A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Launched by MIND MEDICINE, INC. · Apr 16, 2025

Keywords

ClinConnect Summary

The Emerge trial is a research study looking at a new treatment called MM120 for people with Major Depressive Disorder (MDD). This study is in its final phase, which means it’s testing how well MM120 works compared to a placebo (a treatment that looks like the real thing but has no active ingredients) in helping people who are currently experiencing a major depressive episode. The trial is currently recruiting participants aged 18 to 74 who have been dealing with depression for at least 8 weeks but no longer than 24 months, and who meet certain other criteria.

If you or someone you know is interested in participating, it’s important to know that participants will be randomly assigned to receive either MM120 or a placebo. Throughout the study, researchers will monitor participants’ progress to see how they respond to the treatment. To be eligible, participants should not have other major psychiatric disorders or significant health issues, and they should not have a family history of certain mental health conditions. This trial is a great opportunity for individuals looking for new treatment options for depression, and it aims to provide valuable information about the effectiveness of MM120.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of MDD per DSM-5
• • 2. Male or female aged 18 to 74
• • 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration
• • 4. MADRS Total Score ≥26
• • 5. CGI-S Score ≥4
• Exclusion Criteria:
• • 1. Certain psychiatric disorders (other than major depressive disorder)
• • 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
• • 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine
• • 4. Any clinically significant unstable illness